These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19013763)

  • 1. Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review.
    Roundtree AK; Kallen MA; Lopez-Olivo MA; Kimmel B; Skidmore B; Ortiz Z; Cox V; Suarez-Almazor ME
    J Clin Epidemiol; 2009 Feb; 62(2):128-37. PubMed ID: 19013763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
    Kristensen LE; Christensen R; Bliddal H; Geborek P; Danneskiold-Samsøe B; Saxne T
    Scand J Rheumatol; 2007; 36(6):411-7. PubMed ID: 18092260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rituximab in patients with rheumatoid arthritis: systematic review].
    Brodszky V; Czirják L; Géher P; Hodinka L; Kárpáti K; Péntek M; Poór G; Szekanecz Z; Gulácsi L
    Orv Hetil; 2007 Oct; 148(40):1883-93. PubMed ID: 17905683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
    Wiens A; Venson R; Correr CJ; Otuki MF; Pontarolo R
    Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis.
    Seriolo B; Paolino S; Ferrone C; Cutolo M
    Clin Rheumatol; 2007 Oct; 26(10):1799-800. PubMed ID: 17646897
    [No Abstract]   [Full Text] [Related]  

  • 6. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
    Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
    Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence-based practice by biased information from systematic reviews: the case of etanercept and infliximab for the treatment of psoriatic arthritis.
    Corrao S; Puleo A; Pistone G; Calvo L; Scaglione R; Licata G
    Clin Exp Rheumatol; 2008; 26(1):164; author reply 165. PubMed ID: 18328174
    [No Abstract]   [Full Text] [Related]  

  • 8. Guidance for practitioners on the assessment, administration and monitoring of biologic therapies for inflammatory arthritis.
    Oliver S
    Musculoskeletal Care; 2003 Sep; 1(2):135-40. PubMed ID: 20217674
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
    Koike R; Takeuchi T; Eguchi K; Miyasaka N;
    Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
    Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
    Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.
    Francis S; Block MJ
    Arthritis Rheum; 2010 Sep; 62(9):2826; author reply 2826-8. PubMed ID: 20556822
    [No Abstract]   [Full Text] [Related]  

  • 13. [Systematic review: safety and efficacy of anti-TNF in elderly patients].
    Busquets N; Carmona L; Surís X
    Reumatol Clin; 2011; 7(2):104-12. PubMed ID: 21794793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?
    Yazici Y; Erkan D
    Ann Rheum Dis; 2004 May; 63(5):607-8; author reply 608. PubMed ID: 15082503
    [No Abstract]   [Full Text] [Related]  

  • 15. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
    de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L
    Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.
    Furst DE; Gaylis N; Bray V; Olech E; Yocum D; Ritter J; Weisman M; Wallace DJ; Crues J; Khanna D; Eckel G; Yeilding N; Callegari P; Visvanathan S; Rojas J; Hegedus R; George L; Mamun K; Gilmer K; Troum O
    Ann Rheum Dis; 2007 Jul; 66(7):893-9. PubMed ID: 17412737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.
    Woolacott NF; Khadjesari ZC; Bruce IN; Riemsma RP
    Clin Exp Rheumatol; 2006; 24(5):587-93. PubMed ID: 17181932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.